Literature DB >> 27504851

Steroid Metabolomic Disease Signature of Nonsyndromic Childhood Obesity.

Aneta Gawlik1, Michael Shmoish1, Michaela F Hartmann1, Ewa Malecka-Tendera1, Stefan A Wudy1, Ze'ev Hochberg1.   

Abstract

CONTEXT: The profile of urinary steroids as measured by gas chromatography-mass spectrometry defines a subject's "steroidal fingerprint."
OBJECTIVE: Here, we clustered steroidal fingerprints to characterize patients with nonsyndromic childhood obesity by "steroid metabolomic signatures." HYPOTHESIS: Nonsyndromic obesity is a symptom of different diseases and conditions, some of them will have their own signature.
DESIGN: A total of 31 steroid metabolites were quantified by gas chromatography-mass spectrometry, and their excretion rates were z-transformed. Using MetaboAnalyst 3.0, we divided the subjects into 5 distinctive groups by k-means clustering. Steroidal fingerprints and clinical/biochemical data of patients in each cluster were analyzed. PATIENTS: A total of 87 obese children (44 females), aged 8.5-17.9 years, were clinically characterized, and their 24-hour urine was collected.
RESULTS: Cluster 1 (n = 39, 21 females) had normal steroid profile. Cluster 2 (n = 20, 11 females) showed mild, nonspecific elevation of C19 and C21 steroids, females' resistance to polycystic ovary morphology, and hirsutism. Cluster 3 (n = 7 female), with relative 21-hydroxylase insufficiency, was characterized by partial or full polycystic ovary syndrome. Cluster 4 (n = 4 males), showed markedly elevated C21 steroids and imbalance in the 11β-hydroxysteroid dehydrogenase system, higher insulin, increased frequency of glucose/insulin index more than 0.3, γ-glutamyl transpeptidase activity, systolic blood pressure, and tendency to liver steatosis. Cluster 5 (n = 17, 5 females) had elevated dehydroepiandrosterone and 17-OH-pregnenolone metabolites, suggesting 3β-hydroxysteroid dehydrogenase insufficiency but no clinically unique phenotype. Z-score body mass index values were not significantly different between the clusters.
CONCLUSIONS: We defined a novel concept of disease-specific steroid metabolomic signature based on urinary steroidal gas chromatography-mass spectrometry. Clustering by software designed for metabolic data analysis reclassified childhood obesity into 5 groups with distinctive signatures; groups require further definition and may require cluster-specific therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27504851     DOI: 10.1210/jc.2016-1754

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

Review 1.  Metabolomics prospect of obesity and metabolic syndrome; a systematic review.

Authors:  Moloud Payab; Akram Tayanloo-Beik; Khadijeh Falahzadeh; Maryamossadat Mousavi; Saeede Salehi; Shirin Djalalinia; Mahbube Ebrahimpur; Nafiseh Rezaei; Mostafa Rezaei-Tavirani; Bagher Larijani; Babak Arjmand; Kambiz Gilany
Journal:  J Diabetes Metab Disord       Date:  2021-11-26

Review 2.  Update on adrenarche.

Authors:  Selma Feldman Witchel; Bianca Pinto; Anne Claire Burghard; Sharon E Oberfield
Journal:  Curr Opin Pediatr       Date:  2020-08       Impact factor: 2.856

Review 3.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

4.  Longitudinal analyses of the steroid metabolome in obese PCOS girls with weight loss.

Authors:  Thomas Reinehr; Alexandra Kulle; Juliane Rothermel; Caroline Knop-Schmenn; Nina Lass; Christina Bosse; Paul-Martin Holterhus
Journal:  Endocr Connect       Date:  2017-04-03       Impact factor: 3.335

5.  Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies.

Authors:  Oscar Daniel Rangel-Huerta; Belén Pastor-Villaescusa; Angel Gil
Journal:  Metabolomics       Date:  2019-06-13       Impact factor: 4.290

6.  Steroid metabolomic signature of liver disease in nonsyndromic childhood obesity.

Authors:  Aneta Gawlik; Michael Shmoish; Michaela F Hartmann; Stefan A Wudy; Zbigniew Olczak; Katarzyna Gruszczynska; Ze'ev Hochberg
Journal:  Endocr Connect       Date:  2019-06       Impact factor: 3.335

7.  Exploring the Temporal Relation between Body Mass Index and Corticosteroid Metabolite Excretion in Childhood.

Authors:  Britt J Van Keulen; Conor V Dolan; Ruth Andrew; Brian R Walker; Hilleke E Hulshoff Pol; Dorret I Boomsma; Joost Rotteveel; Martijn J J Finken
Journal:  Nutrients       Date:  2020-05-23       Impact factor: 5.717

8.  Untargeted Metabolomics Analysis of the Serum Metabolic Signature of Childhood Obesity.

Authors:  Lukasz Szczerbinski; Gladys Wojciechowska; Adam Olichwier; Mark A Taylor; Urszula Puchta; Paulina Konopka; Adam Paszko; Anna Citko; Joanna Goscik; Oliver Fiehn; Sili Fan; Anna Wasilewska; Katarzyna Taranta-Janusz; Adam Kretowski
Journal:  Nutrients       Date:  2022-01-04       Impact factor: 5.717

9.  Role of glucocorticoid metabolism in childhood obesity-associated hypertension.

Authors:  Martijn J J Finken; Aleid J G Wirix; Ines A von Rosenstiel-Jadoul; Bibian van der Voorn; Mai J M Chinapaw; Michaela F Hartmann; Joana E Kist-van Holthe; Stefan A Wudy; Joost Rotteveel
Journal:  Endocr Connect       Date:  2022-07-14       Impact factor: 3.221

10.  Metabolomic Signatures for the Effects of Weight Loss Interventions on Severe Obesity in Children and Adolescents.

Authors:  Min-Ji Sohn; Woori Chae; Jae-Sung Ko; Joo-Youn Cho; Ji-Eun Kim; Ji-Yeob Choi; Han-Byul Jang; Hye-Ja Lee; Sang-Ick Park; Kyung-Hee Park; Peter J van der Spek; Jin-Soo Moon
Journal:  Metabolites       Date:  2021-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.